BioQ Devices Pty Ltd

BioQ Devices is a pre-clinical stage medical device company developing patented extra aortic balloon counterpulsation technology that targets drug resistance hypertension and moderate heart failure suffers. Over 5 million patients suffer heart failure in the USA alone and at least 1 million of this group are suitable for treatment using the BioQ Cardiac Assist system. The minimum global market opportunity for the BioQ CAS has been valued at over USD$1 Billion/year and is estimated to grow in excess of the CRT/D market of $3B pa. The device can be used to treat hypertension and targets the additional market opportunity of 24% of the 73 million people in the United States with inadequate control of their hypertension. The self-powered extra aortic counterpulsation system being developed by BioQ, treat’s heart failure by reducing afterload and increasing coronary artery blood flow, using the proven principles of aortic counterpulsation delivered in a new revolutionary approach that is aimed at reducing treatment risks and enhancing treatment outcomes in a cost effective and preventative manner. For more information on BioQ Devices, email info@bioqdevices.com